Pipeline Selector Analysis

Patent expiry dates for the active ingredient usually drive the decision of when to market a generic product, however the market opportunity may be constrained by later patents which cannot be circumvented without significant research and development. Other constraints such as data exclusivity may also delay launch of generic pharmaceutical products. Ideally these constraints should be identified early so that plans can be re-structured to account for delayed product launch and/or additional development time and expense.

Based on a GenericsWeb Pipeline Selector report, our Selector Analysis is intended to interpret the report based upon the specific project requirements of the customer. This enables timely project selection and maximised use of limited internal resources, before committing to significant development expense.

Please visit www.genericsweb.com for further details of the beneficial information contained in a Pipeline Selector report.

Please contact us for more information or a quotation for this service.